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Rational Design of Antirheumatic Prodrugs Specific for
Sites of Inflammation
Shimobi C. Onuoha,1 Mathieu Ferrari,1 Daniele Sblattero,2 and Costantino Pitzalis1
Objective. Biologic drugs, such as the anti–tumor
necrosis factor (anti-TNF) antibody adalimumab, have
represented a breakthrough in the treatment of rheuma-
toid arthritis. Yet, concerns remain over their lack of effi-
cacy in a sizable proportion of patients and their potential
for systemic side effects such as infection. Improved bio-
logic prodrugs specifically targeted to the site of inflam-
mation have the potential to alleviate current concerns
surrounding biologic anticytokine therapies. The purpose
of this study was to design, construct, and evaluate in
vitro and ex vivo the targeting and antiinflammatory
capacity of activatable bispecific antibodies.
Methods. Activatable dual variable domain (aDVD)
antibodies were designed and constructed to target
intercellular adhesion molecule 1 (ICAM-1), which is
up-regulated at sites of inflammation, and anti-TNF
antibodies (adalimumab and infliximab). These bispe-
cific molecules included an external arm that targets
ICAM-1 and an internal arm that comprises the thera-
peutic domain of an anti-TNF antibody. Both arms
were linked to matrix metalloproteinase (MMP)–cleav-
able linkers. The constructs were tested for their ability
to bind and neutralize both in vitro and ex vivo targets.
Results. Intact aDVD constructs demonstrated
significantly reduced binding and anti-TNF activity in
the prodrug formulation as compared to the parent
antibodies. Human synovial fluid and physiologic con-
centrations of MMP enzyme were capable of cleaving
the external domain of the antibody, revealing a fully
active molecule. Activated antibodies retained the same
binding and anti-TNF inhibitory capacities as the par-
ent molecules.
Conclusion. The design of a biologic prodrug
with enhanced specificity for sites of inflammation
(synovium) and reduced specificity for off-target TNF is
described. This construct has the potential to form a
platform technology that is capable of enhancing the
therapeutic index of drugs for the treatment of RA and
other inflammatory diseases.
Rheumatoid arthritis (RA) is a systemic inflam-
matory condition that primarily affects synovial joints. It
is characterized by persistent synovitis and destruction
of bone and cartilage. RA affects ;1% of the adult pop-
ulation, with a higher prevalence in the population over
60 years of age (2%) and a 3-fold higher incidence in
women (1). While the cause of the disease remains
incompletely understood, it is known that proinflamma-
tory cytokines play a role in its pathogenesis by sustain-
ing inflammation, which leads to joint destruction (2).
Key cytokines in the development of RA include tumor
necrosis factor (TNF), interleukin-1b (IL-1b), and IL-6.
These cytokines can stimulate the production of matrix
metalloproteinase (MMP) enzymes, destroying the ex-
tracellular matrix and leading to cartilage and bone
damage (3). Collagenases MMP-1 and MMP-13 play a
significant role in RA, as they are shown to be the rate-
limiting step in the process of collagen degradation (4).
In recent years, the availability of biologic drugs
has revolutionized the field of RA treatment. Nonethe-
less, the disease continues to be linked to severe pain,
depression, and impaired function, with 20–40% of
patients failing to respond to current therapy (5,6). The
cost of treating RA with biologic agents is far higher
than the cost of “conventional” disease-modifying anti-
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rheumatic drugs (DMARDs) and continues to be linked
to negative consequences of organ toxicity (7). Targeting
TNF with monoclonal antibodies such as adalimumab
(Humira; AbbVie) and infliximab (Remicade; Janssen
Biologics), either alone or in combination with other
DMARDs, has become the gold standard for RA therapy
(8). While TNF has a highly deleterious effect in inflam-
matory joint diseases, it plays a vital role in the body’s
defenses against infection (9). In the immune response to
Mycobacterium tuberculosis, TNF plays a critical protec-
tive role, leading to macrophage activation, cell recruit-
ment, granuloma formation, and maintenance of
granuloma integrity (10–12). Thus, systemic blockade of
TNF increases the risk of tuberculosis infection and reac-
tivation in patients with latent disease, as compared to
alternative DMARD therapy (13). Although the exact
mechanism behind the high number of nonresponders to
anti-TNF biologic therapy is not clear (14), it is plausible
to hypothesize that a lack of efficacy may be due to sub-
optimal TNF blockade at sites of inflammation, which
cannot be improved by increased systemic administration
because of potential general toxicity when taken at doses
higher than those recommended (15,16).
A possible solution would be to develop new
agents with dual specificity, in which one domain targets
molecules expressed at high levels (e.g., cell adhesion
molecules) at the site of disease (the synovium in the
case of RA) and the other domain targets the cytokine
of interest (e.g., TNF). Bispecific agents, such as dual
variable-domain immunoglobulins (DVD-Ig) (17),
could theoretically deliver higher local concentrations
with lower systemic exposure. In this format, the vari-
able domains of 2 distinct monoclonal antibodies are
linked, creating a tetravalent, dual-targeting single
agent. While it has been shown that viable DVD-Ig mol-
ecules can be identified through optimization of an anti-
body pair, antibody variable domain orientation, and
linkers, an ongoing limitation of the technology is the
lower binding affinity observed by the “inner domain”
as compared to the “outer domain.” Several bodies of
work have investigated the possibility of increasing the
viability of the inner domain by using variable linkers,
and it has been suggested that each antibody needs to
be optimized individually in terms of inner/outer
domain arrangement and linker length construction to
derive the best molecule (18,19).
By reversing the concept, the intrinsic reduced
activity of the inner domain represents an advantage in
the design of an antibody-based “prodrug”-targeting mol-
ecule, with an outer domain capable of targeting the
inflamed synovium and an inner domain that binds TNF.
We hypothesized that by varying the linker length, it
would be possible to reduce the binding affinity of the
inner domain to TNF in its circulating unbound form
while maintaining the specificity of the outer domain for
the target of interest. This, coupled with further engineer-
ing of the linker to contain an MMP-cleavable sequence,
would allow a fully functional antibody to be released and
to act locally at the site of inflammation. Such a molecule,
which we identify as an activatable DVD (aDVD), would
have the benefits of reducing systemic toxicity while
increasing the therapeutic dosage available at sites of dis-
ease, thus improving its therapeutic index.
MATERIALS AND METHODS
Cloning and expression of DVD antibodies. The se-
quences of the variable regions of anti-human ICAM-1 anti-
body and human TNF have been previously described (20,21).
Sequence data management was performed using Serial Cloner
2.6. Variable sequences were generated by gene synthesis (Gen-
Script) and combined into various constructs using overlapping-
extension polymerase chain reaction (PCR) (22). The PCR
products were cloned into the AbVec-hIgG1 and AbVec-hIgK
vectors (23) using the restriction sites Age I–Sal I and Age I–Bsi
WI, respectively. Clones were sequence-verified prior to protein
expression.
Twenty-four hours before transfection, vectors encod-
ing the heavy and light chains of the DVD antibody were trans-
fected into HEK 293T cells in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum (FBS),
100 units/ml of penicillin, 100 mg/ml of streptomycin, and
0.5 mg/ml of Geneticin. Transfection was performed with Jet-
Prime reagent (Polyplus) according to the manufacturer’s pro-
tocol. The antibodies were purified from the supernatant via
affinity chromatography using protein A–Sepharose CL-4B
(GE Healthcare). DVD antibodies were biotinylated using an
EZ-Link Sulfo-NHS-SS biotinylation kit (Thermo-Fisher Scien-
tific) according to the manufacturer’s protocol.
MMP enzymatic digestion. Antibodies were incubat-
ed at 378C at a concentration of 100 mg/ml with 35 units of
recombinant MMP-1 enzyme (Enzo Life Sciences) in 50 mM
Tris, 0.15M NaCl, 10 mM CaCl2, 50 mM ZnCl2, and 0.02%
Brij35. Antibodies used for kinetic analysis were digested for 1
hour at 378C. Digestion with RA synovial fluid (SF) and RA
serum was performed by incubating 500 ng of biotinylated
antibody in 200 ml of fluid at 378C for 24–72 hours in the pres-
ence of 20 mM GM6001 (MMP inhibitor).
Protein characterization. Protein purity and molecu-
lar weight were assessed by resolution in sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis (SDS-PAGE) reducing
gels using Mini-Protean 4–20% TGX gels (Bio-Rad) followed
by Sypro Ruby protein gel stain according to the manufacturer’s
instructions. Western blot analysis of antibodies digested with
RA SF and serum was performed via nitrocellulose transfer.
Biotinylated antibody heavy and light chains were detected
using streptavidin–horseradish peroxidase (HRP).
Quantification of anti-TNF activity. Enzyme-linked
immunosorbent assay (ELISA) of anti-TNF activity was per-
formed in 96-well plates (Thermo-Fisher Scientific) that had
been coated overnight at 48C with 100 ng/ml of TNF in phos-
phate buffered saline (PBS). Plates were blocked for 2 hours
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at room temperature with PBS/2% bovine serum albumin and
then incubated with serial dilutions of DVD antibody. Bound
antibodies were detected with HRP-conjugated anti-human
IgG antibody (Jackson Immunotools). Plates were then incu-
bated with tetramethylbenzidine substrate (GE Healthcare),
and reactions were stopped with 1N H2SO4. Optical absorp-
tion was measured at 450 nm. The 20% effective concentration
(EC20) was calculated using a dose-response nonlinear-fit
curve in GraphPad Prism v5.
Inhibition of TNF-induced cytotoxicity was conducted
in the L929 cell line. Briefly, 3 3 104 cells were seeded in 96-
well plates for 18 hours at 378C in 100 ml of DMEM supple-
mented with 10% FBS, 100 units/ml of penicillin, 100 mg/ml of
streptomycin, and a 10 mM concentration of the MMP inhibi-
tor GM6001. The medium was then replaced with 100 ml of
complete medium with 1 mg/ml of actinomycin D and 0.45 ng/
ml of either TNF (Sigma) or TNF plus the antibody of interest
(1:2 serial dilutions), and this was incubated for 24 hours at
378C. We added 500 mg/ml of thiazolyl blue tetrazolium bro-
mide in PBS (Sigma) to the wells and incubated them for
3 hours at 378C. Medium was then removed, and the cells
were resuspended in 100 ml of 90% isopropanol 10% DMSO
for 15 minutes. Optical absorption was measured at 595 nm.
The percentage of viable cells was calculated as follows:
(OD595 nm 3 100)/OD595 nm of sample without TNF. The 20%
inhibition concentration (IC20) was determined using a dose-
response nonlinear-fit curve in GraphPad Prism v5.
Surface plasmon resonance (SPR). SPR experiments
were performed with a Biacore T200 instrument using HBS-
P1 as the running and dilution buffer (GE Healthcare Bio-
Sciences). BIAevaluation software version 2.0 (GE Health-
care) was used for data processing. For determination of the
Figure 1. Structure and characterization of activatable dual variable-domain (aDVD) antibodies. A, Schematic representation of the general
structure of DVD constructs with an anti–intercellular adhesion molecule 1 (anti–ICAM-1) outer domain linked to the anti–tumor necrosis
factor (anti-TNF) antibody adalimumab. Variable heavy (VH), constant heavy (CH), variable light (VL), and constant light (CL) chain regions
are indicated. Linker length and amino acid composition are summarized in the table, with the matrix metalloproteinase (MMP)–cleavable
sequence in boldface and the cutting position marked with a slash. HC5 heavy chain; LC5 light chain. B, Time course of aDVD antibody
cleavage with recombinant MMP as resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis. The gel shows a gradual conver-
sion from DVD heavy chain to IgG heavy chain as a result of cleavage and removal of the outer anti–ICAM-1 variable region. Similar proc-
essing was detected on the light chain (results not shown). C, Western blot analysis under reducing conditions. The time-dependent increase
in IgG heavy chain content due to cleavage of the biotinylated aDVD antibody carrying the short MMP-cleavable linker, following incubation
with rheumatoid arthritis (RA) synovial fluid (SF) at 378C, can be seen. No cleavage was detected at 72 hours for the antibody carrying the
scrambled MMP linker, nor was any cleavage detected upon incubation with RA serum or incubation in the presence of the MMP inhibitor
GM6001.
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binding kinetics, mouse anti-human IgG (GE Healthcare) was
covalently coupled to a CM5 Sensor Chip (GE Healthcare).
Human antibody or DVD antibody was captured, and various
concentrations of interaction partner protein were injected
over the flow cell at a flow rate of 30 ml/minute. A double-
reference subtraction was performed using buffer alone.
Kinetic rate constants were obtained by curve fitting according
to a 1:1 Langmuir binding model.
Immunohistochemical analysis. Formalin-fixed para-
ffin-embedded tissue sections were dewaxed, and antigens
were retrieved after 10 minutes of boiling in citrate buffer, pH
6 (Dako). Slides were stained with 10 mg/ml of biotinylated
DVD antibodies for 1 hour at room temperature and were
visualized with streptavidin–HRP complex using 3,30-diamino-
benzidine chromogen (Dako). Rabbit anti–ICAM-1 IgG
(Abcam) was detected with HRP-conjugated goat anti-rabbit
IgG (Jackson Immunotools). Mouse anti–von Willebrand factor
(Dako) and mouse anti-CD31 (R&D Systems) were used to
identify human vascular endothelial cells, which were revealed
with HRP-conjugated goat anti-mouse IgG (Santa Cruz Bio-
technology). Sections were counterstained with hematoxylin,
mounted with Depex mounting medium (Dako), and acquired
with a CellSens imaging system (Olympus).
RESULTS
Design and cleavage of an activatable dual
variable-domain antibody. To create a bispecific anti-
body format with therapeutic activity in RA and target-
ing capacity for the inflamed synovium, the gold
standard for anti-TNF biologic drugs, adalimumab, was
coupled with an ICAM-1–targeting antibody, using an
adaptation of the well-established DVD-Ig format (17).
The construct we describe contains the anti–ICAM-1
VL and VH domains linked to the light chain and heavy
chain, respectively, of the anti-TNF drug adalimumab
via a small peptide linker (Figure 1A). To create a DVD
bispecific antibody with impaired binding capacity for
the internal variable domain, a series of linkers with var-
ious lengths and amino acid compositions were designed
to test for the desired activity (Figure 1A). The long
linker was derived from a natural linker found in human
IgG antibodies and was previously described in the con-
text of the DVD-Ig format (24). Reducing the linker
length can substantially alter the kinetic properties of
the internal binding domain (24).
We hypothesized that short linkers could impair
the accessibility of the ligand to the internal domain in
such a way that could be reverted upon cleavage of the
internal linker, thus forming an activatable DVD pro-
drug. The remaining 4 linkers contained an MMP-
cleavable site (PLGLWA) (25), either alone or in the
presence of G4S-flanking regions, and a scrambled
MMP-cleavable sequence (AGPLLW). To test the abili-
ty of the MMP enzyme to access, cleave, and activate
the internal anti-TNF domain, the aDVD constructs
where incubated with physiologically relevant concen-
trations of recombinant MMP enzyme. Analysis of the
digested aDVD constructs by reduced SDS-PAGE (Fig-
ure 1B) showed rapid processing of the aDVD carrying
the MMP cleavable site, with the formation of molecu-
lar weight products consistent with an IgG format.
Incubation of the aDVD construct carrying the
short MMP linker (PLGLWA) with SF from RA
patients also showed time-dependent activation of the
construct, confirming the processing capacity under
physiologic conditions (Figure 1C). Activation using SF
was less efficient than that observed with recombinant
protein. This may be due to saturation of MMP activity
in ex vivo assays, which one would not anticipate to
occur in vivo during chronic inflammation, where MMP
expression in the synovial tissue is expected to be higher
than in the surrounding SF (26). Additionally, the cleav-
age could be inhibited by the MMP inhibitor GM6001,
while no cleavage could be detected for the aDVD car-
rying the scrambled MMP linker, further confirming
MMP-mediated activation of the constructs.
Impaired binding of aDVD to TNF and rescue
by MMP cleavage. To be effective as a targeting pro-
drug, it is important that the aDVD molecules retain
their ability to bind to their target antigen via the outer
binding domain, while the inner domain remains
shielded. The binding of aDVD molecules to ICAM-1
(outer domain) and TNF (inner domain) was investigat-
ed via ELISA. The uncut aDVD molecules retained
their binding to ICAM-1 to the same extent as the par-
ent anti–ICAM-1 antibody (data not shown). However,
before MMP cleavage, the molecules showed a 275-fold
reduction in binding to TNF as compared to adalimu-
mab IgG. Binding to TNF was fully rescued for all the
constructs following MMP cleavage (Figure 2A).
We used the L929 assay to assess the ability of
the aDVD constructs to inhibit ligand binding to its
receptor and to prevent TNF-induced cytotoxicity. The
ability of the uncleaved aDVD construct to block and
inhibit TNF was severely impaired, consistent with the
binding data obtained by ELISA. The uncleaved aDVD
antibodies showed up to a 132-fold increase in the IC20
as compared to adalimumab IgG, while cleavage with
MMP completely rescued the inhibitory capacity (Fig-
ure 2B). As expected, the short MMP-cleavable linker
(PLGLWA) was characterized by a greater TNF bind-
ing impairment and was further validated using SPR.
We also compared the affinities of the restricted
and processed forms of the aDVD molecule (Table 1).
Binding of TNF to the uncleaved molecule was greatly
impaired, as demonstrated by a 365-fold reduction in
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Figure 2. Anti-TNF activity of DVD antibodies. A, TNF binding capacity for DVD antibodies (Ab) (scrambled MMP and long linker) and
aDVD antibodies (MMP, G4S-MMP-G4S, and [G4S]2-MMP-[G4S]2), as determined by enzyme-linked immunosorbent assay. Reduced binding
capacity was detected for uncut aDVD constructs, while full potency could be restored upon cleavage with MMP enzyme, as compared with ada-
limumab IgG. B, Neutralization of TNF-induced cytotoxicity in the L929 cell functional assay. Neutralization of cytotoxicity was impaired in
uncut aDVD antibodies, with stronger impairment for ICAM-MMP-adalimumab antibody. Potencies similar to that of adalimumab IgG were
obtained following MMP enzymatic digestion. Results in A are expressed as the 20% effective concentration (EC20) and results in B as the 20%
inhibition concentration (IC20), corresponding to the dose necessary to obtain 20% of the activity. Values are the mean6 SEM. See Figure 1 for
other definitions.
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the affinity constant (KD). Observation of the kinetics of
binding indicated that the difference in affinity was pre-
dominantly driven by a reduction in the association rate
constant (Ka), which was 189-fold lower than that for the
uncleaved molecule, whereas the dissociation rate constant
(Kd) was largely unchanged (Figure 3A and Table 1). This
result demonstrated that blocking of the external domain
acts primarily by inhibiting association through steric hin-
drance; however, once bound, the antibody retains similar
binding characteristics, indicating that the internal domain
has not been modified and remains fully functional. Impor-
tantly, cleaved aDVD molecules showed not only identical
affinity, but also identical component kinetics of binding to
the parent adalimumab antibody (Table 1). In both cases,
the binding kinetics were in good agreement with previous-
ly reported data (27).
In order to target proteins in a disease setting, the
aDVD needs to maintain its cleavage capacity in the
presence of both targeting and effector antigens, as is
likely to be the scenario in the cytokine-rich environment
of the inflamed synovium. This is particularly pertinent
as the aDVD is still capable of binding to TNF with a
slow dissociation rate, which could conceivably block the
cleavage site by steric hindrance (Figure 3A). In order to
observe whether the aDVD molecule could be cleaved
and activated in this environment, the molecule was
immobilized on an SPR sensor chip, and saturating con-
centrations of TNF were injected, followed by ICAM-1,
prior to MMP cleavage on the sensor surface (Figure
3B). TNF showed the same restricted level of binding as
had previously been demonstrated with the uncut materi-
al. ICAM-1, however, was capable of binding to the mol-
ecule in the presence of TNF, as demonstrated by the
observed change in response units, which was of the
same magnitude as ICAM-1 injected onto free antibody
at the same concentration (data not shown).
In the presence of both saturating concentrations
of ICAM-1 and TNF, MMP enzyme was injected over a
period of 30 minutes. Following chip cleavage and a
period of stabilization to remove unbound material
from the chip surface, the chip was rechallenged with
TNF. Postcleavage, the TNF binding capacity was res-
cued, as demonstrated by the enhanced change in
response units, which was measured at the same level as
the injected concentration on the unrestricted antibody
(Figures 3A and B).
Tissue-specific targeting using the aDVD anti-
body platform. One of the key characteristics of the
aDVD format is the ability to present the anti-TNF
therapeutic function in a prodrug format that can be
activated following encounter with MMP enzymes at the
site of arthritic inflammation. The presence of the outer
variable-domain–targeting ICAM-1, an integrin overex-
pressed in inflammatory conditions such as RA (28,29),
would allow the preferential accumulation of antibody
in the target tissue, facilitating the encounter with pro-
teolytic enzymes. MMP cleavage causes the removal of
the anti–ICAM-1 external domain, resulting in loss of
ICAM-1 specificity (data not shown). To test the ability
of the aDVD to retain tissue-targeting capacity when in
full conformation, we examined its reactivity with the
microvasculature in samples of human synovium
obtained from 3 RA patients, 3 osteoarthritis patients,
and a patient without arthritis (normal synovium) via
immunohistochemistry (Figure 4).
The ICAM-MMP-adalimumab aDVD was able
to selectively target the human inflamed synovium from
both the RA patients and the OA patients with similar
efficacy as compared to an anti–ICAM-1 IgG antibody.
Importantly, no detectable reactivity was identified in
the normal synovium sample from a patient without
arthritis. The specificity for arthritic synovium further
strengthens the potential of the aDVD for use in tar-
geted drug delivery in RA.
Furthermore, the aDVD format may represent a
flexible platform for targeted delivery of prodrugs that
Table 1. Surface plasmon resonance kinetic measurements of aDVD antibodies*
Molecule Substrate Ka, 1/msec Kd, 1/second KD, pM
Adalimumab IgG TNF 2.416 3 106 1.192 3 1024 49.3
aDVD ICAM-MMP-adalimumab
Cleaved TNF 2.047 3 106 1.087 3 1024 53.1
Uncleaved TNF 1.08 3 104 1.83 3 1024 18,000
Infliximab IgG TNF 4.04 3 106 2.5 3 1024 61.8
aDVD ICAM-MMP-infliximab
Cleaved TNF 2.98 3 106 3.66 3 1024 123
Uncleaved TNF 3.8 3 103 6 3 1024 158,000
* Activatable dual variable-domain (aDVD) antibody constructs targeting intercellular adhesion molecule 1
(ICAM-1) and the anti–tumor necrosis factor (anti-TNF) antibodies adalimumab and infliximab were designed
with matrix metalloproteinase (MMP)–cleavable linkers as described in Materials and Methods. Ka5 associa-
tion rate constant; Kd5 dissociation rate constant; KD5 affinity constant.
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Figure 3. Analysis of the antigen-binding kinetics of aDVD. A, Surface plasmon resonance sensorgrams showing the binding kinetics of adalimu-
mab IgG, aDVD, and recombinant MMP–cleaved aDVD to TNF. The reduced binding capacity of aDVD for TNF could be reverted following
digestion with MMP enzyme, restoring its full binding potential as compared to adalimumab IgG (see Table 1 for kinetic measurements). TNF
concentrations were 20 nM (red), 8 nM (yellow), 3.2 nM (green), 1.28 nM (blue), and 0.512 nM (purple). B, Dynamic binding kinetics for TNF
and ICAM-1. When the aDVD antibody had been saturated with TNF of limited binding capacity, the second antigen was injected, showing
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can be easily adapted to other cytokines and to other
disease conditions with a simple exchange of the outer
targeting domain.
Improvement in the structural design of aDVD
molecules with knowledge of the molecular interac-
tions. Since the reduced binding of aDVD molecules
can be mediated by blocking of the internal domain, we
hypothesized that further inhibition of binding could be
predicted through knowledge of the interaction between
TNF and the inner domain antibody. The crystal struc-
tures of adalimumab and infliximab in complex with
TNF have recently been reported (30,31). Crystal struc-
ture data showed that adalimumab bound to trimeric
TNF via a broader binding interface, with a total buried
surface area of 2,540 A˚2 (31), while infliximab bound
to the TNF trimer via a reduced binding interface of
1,977 A˚2 (Figure 5A). Additionally, adalimumab
engages the TNF trimer through interactions with 2
monomers of the trimer, while the binding of infliximab
is mediated almost exclusively through the loop region
of a single TNF monomer. We therefore predicted that
the smaller interaction surface area in the infliximab–
TNF complex would translate to a binding interface that
would be more readily blocked by the outer domain. To
test this, an aDVD molecule was engineered with inflixi-
mab as the inner binding domain and was tested for
binding and functionality.
Infliximab bound to TNF with an EC20 of 0.004
nM, while the aDVD-infliximab bound with an EC20 of
21.6 nM. Once processed by MMP cleavage the antibody
demonstrated binding that was comparable to the origi-
nal infliximab antibody (Figure 5B). The fold difference
between cleaved and uncleaved aDVD-infliximab
antibody was 3,000, which was 10-fold higher than the
difference measured for the aDVD-adalimumab con-
struct. The ability of the antibody to inhibit TNF bind-
ing to its receptor in L929 cell functional studies was
also greatly diminished, as no anti-TNF functionality
could be detected for the uncleaved aDVD-infliximab
over the range of concentrations tested, while activity
was fully rescued after linker cleavage (Figure 5C).
SPR data demonstrated a 2,500-fold reduction in the
KD that was predominantly driven by a reduction in
the Ka, with an observed 1,000-fold reduction in the
Figure 4. Human synovial tissue reactivity of aDVD antibodies. The reactivity of the ICAM-1-MMP-adalimumab construct with RA, osteoar-
thritis (OA), and nonarthritic (normal) human synovial tissues was examined using immunohistochemistry. Bound biotinylated aDVD antibodies
were detected using streptavidin–horseradish peroxidase complex and compared to the staining pattern of anti–ICAM-1 IgG. The presence of
blood vessels was depicted using anti–von Willebrand factor (anti-vWF) antibody in combination with anti-CD31 antibody. Biotinylated human
IgG was used as the negative control. Bars5 100 mm. See Figure 1 for other definitions.
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association constant (Figure 5D and Table 1). These
data further demonstrated the flexibility with which dif-
ferent binding moieties can be introduced and
highlighted the fact that the molecular interactions
between parent antibody and the target antigen can be
used to design aDVD molecules with more-potent
blocking capacity.
DISCUSSION
The last 2 decades have marked a substantial revo-
lution in the treatment paradigm for RA. The advent of
biologic agents has provided a new avenue for the success-
ful treatment of RA. However, there remain a consider-
able number of patients who do not respond to the
Figure 5. Molecular interactions as determinants of aDVD antibody (Ab) inhibitory properties. A, Schematic representation of the interaction of
infliximab and adalimumab with TNF. There is a reduced contact area (red) for infliximab as compared to that for adalimumab, which may pre-
dict an increased binding inhibition in the aDVD format. Adapted, with permission, from ref. 31 (VC 2013 The American Society for Biochemistry
and Molecular Biology). B, TNF binding capacity for the aDVD ICAM-MMP-infliximab construct. Binding capacities before and after MMP
cleavage were compared to that of infliximab, as determined by enzyme-linked immunosorbent assay. A 2,500-fold inhibition for the infliximab
aDVD construct compared to infliximab was observed, with rescue of the binding upon cleavage of the construct with MMP. C, Neutralization of
TNF-induced cytotoxicity in the L929 cell functional assay. There was a complete loss of function of the ICAM-MMP-infliximab construct as
compared to infliximab. Results in B are expressed as the 20% effective concentration (EC20) and results in C as the 20% inhibition concentra-
tion (IC20). Values are the mean6 SEM. D, Binding kinetics of aDVD ICAM-MMP-infliximab and infliximab to TNF. Results show the binding
of 20 nM TNF to infliximab and ICAM-MMP-infliximab coupled to the sensor surface at the same density. See Figure 1 for other definitions.
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available therapies and in whom a treatment-free remis-
sion is rarely achieved (5,6). RA also represents one of the
most lucrative markets for pharmaceutical companies, and
in 2013, the 3 top-selling drugs were all biologic agents
marketed for the treatment of RA (see EvaluatePharma,
which is available online at http://www.evaluategroup.com/).
Despite the obvious success of the current treatments,
little effort has been invested in improving the safety
profiles of the available therapeutic alternatives.
The identification of tissue-specific or overex-
pressed antigens in the inflamed synovium may provide a
solution to these concerns and allow the development of
therapeutic agents for tissue-specific drug delivery (32).
Several candidates are now being considered for arthritic
synovium targeting, including the oncofetal extradomain
A of fibronectin. Indeed, a single-chain antibody frag-
ment that targets extradomain A has recently entered
clinical evaluation as an scFv-IL-10 fusion protein for the
treatment of RA (ClinicalTrials.gov ID NCT02076659).
An alternative strategy could involve the use of bispecific
antibody to combine tissue targeting with therapeutic
function. To date, no bispecific antibody has been clini-
cally evaluated for use in RA; however, 2 antibodies,
catumaxomab and blinatumomab, have been recently
approved for cancer treatment, and several constructs
are currently in clinical trials (33).
The bispecific antibody format DVD-Ig has
shown potential as a versatile platform for dual-antigen
targeting (17). One of the crucial aspects necessary for a
conventional bispecific antibody is the capacity for real
synergistic activity between the 2 binding moieties. Dif-
ferences in binding affinities may result in targeting
skewed toward one antigen and, as a consequence, sub-
optimal therapeutic activity. This is probably the main
drawback when combining tissue-targeting moieties
with existing therapeutic domains, which are usually
characterized by very high affinities. Interestingly, the
size and composition of the linker between the outer
and inner variable domain of DVD-Ig antibodies has
been shown to significantly affect the kinetic activity of
the inner region (19). We hypothesized that by reducing
the linker length, we could selectively impair antigen
accessibility to the internal domain in a reversible man-
ner, via the presence of an MMP-cleavable site within
the linker. By placing the therapeutic moiety on the
inner region, we could obtain 3 important effects: 1)
binding capacity skewed toward tissue targeting provid-
ed by the outer variable domain, 2) inhibition of system-
ic engagement of the inner therapeutic binding region,
and 3) selective activation of the therapeutic antibody at
the site of local inflammation. This construct would
therefore provide a tissue-specific delivery of an anti-
body prodrug.
We developed an activatable DVD-like construct
with an anti–ICAM-1 outer domain (for targeting the
inflamed synovium) linked to the anti-TNF antibody
adalimumab. The linkers we designed contained an
MMP-cleavable sequence and were readily cleaved by
the proteolytic MMP-1 enzyme, both in recombinant
form and in physiologic form in human RA SF, provid-
ing insight for efficient in vivo antibody activation.
Although MMP overexpression is generally associated
with inflammation, angiogenesis, and wound repair, dif-
ferent tissues/conditions are characterized by increased
expression of specific MMP subgroups. In the context of
inflammation, elevated levels of MMPs 2, 7, 8, and 9
have been reported in experimental autoimmune
encephalomyelitis (34–36), while MMPs 3 and 9 have
been associated with cutaneous inflammation (37). In
inflammatory arthritis, overexpression of MMPs 1, 3, 9,
and 13 has been correlated with disease progression and
joint damage (26,38,39). MMP levels in RA SF and
serum were found to be significantly higher than those
in healthy controls, with SF levels being several
hundred-fold higher than serum levels (39,40).
As synoviocytes in the lining layer represent the
predominant source of MMPs in the arthritic synovium
(41), the synovial tissue can be expected to display a
greater concentration of MMP-1 and MMP-3 than the
associated SF and peripheral blood. The slower anti-
body cleavage rate observed when using RA SF and the
lack of activation in RA sera may result in an advantage
in vivo, where only the antibody that is actively accumu-
lated in the arthritic synovial tissue may be held long
enough for efficient MMP cleavage. Furthermore, in
the context of infections such as tuberculosis (a major
risk of treatment with anti-TNF), the main driver of car-
tilage degradation is MMP-9, with low secreted levels of
MMP-1 (100-fold lower than in RA SF) (42,43). This
may result in increased safety because of a reduced risk
of unwanted antibody activation in other tissues, and/or
it may result in the presence of concomitant infections.
Characterization of the binding of TNF by
ELISA and inhibition of the biologic activity of TNF in
L929 cell assays proved that short linkers could substan-
tially restrict antigen accessibility and binding capacity.
The binding, however, could be fully resolved upon
MMP cleavage. Among the 3 MMP-containing linkers,
the short PLGLWA linker showed the highest binding
inhibition, reasonably due to the vicinity of the outer
domain and increased steric hindrance. Indeed, mea-
surement of the binding kinetics by SPR showed
impaired antigen access to the inner domain, resulting
2670 ONUOHA ET AL
in a slower Ka. Once bound, however, the Kd kinetics for
TNF were unchanged, suggesting unaltered functionali-
ties of adalimumab in the aDVD format. This was fur-
ther confirmed by the identical kinetics of the cleaved
aDVD and the parent adalimumab antibody. This effect
was more pronounced when we used variable regions
with smaller binding interface (e.g., infliximab).
The change of paradigm in the treatment of RA
with the consequent huge costs to national health sys-
tems has spurred the identification of new clinical tools
for stratification of patients in order to improve thera-
peutic effectiveness and reduce adverse effects as well
as costs (44). The next step in increasing the therapeutic
potency and the safety profile would be the develop-
ment of tissue-specific (not only inflammation-specific)
targeting agents (32). With regard to RA synovium, our
group of investigators has previously identified peptides
and scFv antibody fragments with selective specificity
for the synovium (45–47). The incorporation of the scFv
A7 in the aDVD format, as demonstrated herein for
ICAM-1, will provide specificity for human arthritic
synovium to the molecule, with great potential for
tissue-specific drug delivery in RA.
These constructs have the potential to increase
safety because of their selective activation in situ and
their inhibited systemic cytokine engagement and to
increase potency because of their enhanced therapeuti-
cally relevant concentrations achieved at the site of
active disease. We can believe that the development of
tissue-targeting prodrugs such as the aDVD described
herein could represent optimum flexible platforms for
the rational design of therapeutic agents with significant
impact on RA.
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